PortalPublikationenThe use of breast ultrasound for prediction of pathologic co...

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

Standard

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. / Graeser, Monika; Harbeck, Nadia; Gluz, Oleg; Würstlein, Rachel; Zu Eulenburg, Christine; Schumacher, Claudia; Grischke, Eva-Maria; Forstbauer, Helmut; Dimpfl, Moritz; Braun, Michael; Christgen, Matthias; Kreipe, Hans Heinrich; Potenberg, Jochem; von Schumann, Raquel; Aktas, Bahriye; Kolberg-Liedtke, Cornelia; Kümmel, Sherko; Nitz, Ulrike.

in: BREAST, Jahrgang 59, 10.2021, S. 58-66.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Graeser, M, Harbeck, N, Gluz, O, Würstlein, R, Zu Eulenburg, C, Schumacher, C, Grischke, E-M, Forstbauer, H, Dimpfl, M, Braun, M, Christgen, M, Kreipe, HH, Potenberg, J, von Schumann, R, Aktas, B, Kolberg-Liedtke, C, Kümmel, S & Nitz, U 2021, 'The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials', BREAST, Jg. 59, S. 58-66. https://doi.org/10.1016/j.breast.2021.06.001

APA

Graeser, M., Harbeck, N., Gluz, O., Würstlein, R., Zu Eulenburg, C., Schumacher, C., Grischke, E-M., Forstbauer, H., Dimpfl, M., Braun, M., Christgen, M., Kreipe, H. H., Potenberg, J., von Schumann, R., Aktas, B., Kolberg-Liedtke, C., Kümmel, S., & Nitz, U. (2021). The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. BREAST, 59, 58-66. https://doi.org/10.1016/j.breast.2021.06.001

Vancouver

Graeser M, Harbeck N, Gluz O, Würstlein R, Zu Eulenburg C, Schumacher C et al. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. BREAST. 2021 Okt;59:58-66. https://doi.org/10.1016/j.breast.2021.06.001

Bibtex

@article{5efe8223e75d422d8caa39d2419d833b,
title = "The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials",
abstract = "OBJECTIVE: We assessed the value of breast ultrasound (US) performed at week 3 and 6 and at the end (EOT) of neoadjuvant therapy (NAT) for prediction of pathologic complete response (pCR, ypT0/is ypN0) in patients with HR+/HER2+, HR-/HER2-or HR-/HER2+ early breast cancer enrolled in the WSG-ADAPT subtrials.METHODS: US was performed at week 3 and 6 of NAT and at EOT in 401, 517, and 553 patients, respectively. Tumors with complete or partial response by US (RECIST 1.1) were classified as responders and those with stable or progressive disease as non-responders.RESULTS: pCR rate was higher in US responders than in non-responders. US tended to yield the highest positive predictive value in HR-/HER2+ (69%) and HR-/HER2-tumors (65%) at week 3, and the highest negative predictive value in HR+/HER2+ tumors at week 6 and at EOT (88.9% and 86.9%, respectively) and in HR-/HER2-tumors at EOT (87.9%). Multivariable analysis of patients with US at week 3 and 6 identified tumor subtype (HR-/HER2+ vs HR+/HER2+; odds ratio (OR) 2.77, 95%CI 1.45-5.29, and OR 4.17, 95%CI 2.26-7.68, respectively) and each 10% change in lesion dimension on US from baseline (OR 1.15, 95%CI 1.08-1.24, and OR 1.25, 95%CI 1.16-1.35, respectively) as parameters associated with pCR.CONCLUSIONS: Our data support the use of week 3 and EOT US for prediction of pCR in response-guided NAT and in planning of breast-conserving surgery. Change in tumor diameter on US as a continuous variable could be a valuable alternative to categorical RECIST 1.1 criteria.",
keywords = "Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms/drug therapy, Female, Humans, Neoadjuvant Therapy, Receptor, ErbB-2, Ultrasonography, Mammary",
author = "Monika Graeser and Nadia Harbeck and Oleg Gluz and Rachel W{\"u}rstlein and {Zu Eulenburg}, Christine and Claudia Schumacher and Eva-Maria Grischke and Helmut Forstbauer and Moritz Dimpfl and Michael Braun and Matthias Christgen and Kreipe, {Hans Heinrich} and Jochem Potenberg and {von Schumann}, Raquel and Bahriye Aktas and Cornelia Kolberg-Liedtke and Sherko K{\"u}mmel and Ulrike Nitz",
note = "Copyright {\textcopyright} 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2021",
month = oct,
doi = "10.1016/j.breast.2021.06.001",
language = "English",
volume = "59",
pages = "58--66",
journal = "BREAST",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

RIS

TY - JOUR

T1 - The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

AU - Graeser, Monika

AU - Harbeck, Nadia

AU - Gluz, Oleg

AU - Würstlein, Rachel

AU - Zu Eulenburg, Christine

AU - Schumacher, Claudia

AU - Grischke, Eva-Maria

AU - Forstbauer, Helmut

AU - Dimpfl, Moritz

AU - Braun, Michael

AU - Christgen, Matthias

AU - Kreipe, Hans Heinrich

AU - Potenberg, Jochem

AU - von Schumann, Raquel

AU - Aktas, Bahriye

AU - Kolberg-Liedtke, Cornelia

AU - Kümmel, Sherko

AU - Nitz, Ulrike

N1 - Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2021/10

Y1 - 2021/10

N2 - OBJECTIVE: We assessed the value of breast ultrasound (US) performed at week 3 and 6 and at the end (EOT) of neoadjuvant therapy (NAT) for prediction of pathologic complete response (pCR, ypT0/is ypN0) in patients with HR+/HER2+, HR-/HER2-or HR-/HER2+ early breast cancer enrolled in the WSG-ADAPT subtrials.METHODS: US was performed at week 3 and 6 of NAT and at EOT in 401, 517, and 553 patients, respectively. Tumors with complete or partial response by US (RECIST 1.1) were classified as responders and those with stable or progressive disease as non-responders.RESULTS: pCR rate was higher in US responders than in non-responders. US tended to yield the highest positive predictive value in HR-/HER2+ (69%) and HR-/HER2-tumors (65%) at week 3, and the highest negative predictive value in HR+/HER2+ tumors at week 6 and at EOT (88.9% and 86.9%, respectively) and in HR-/HER2-tumors at EOT (87.9%). Multivariable analysis of patients with US at week 3 and 6 identified tumor subtype (HR-/HER2+ vs HR+/HER2+; odds ratio (OR) 2.77, 95%CI 1.45-5.29, and OR 4.17, 95%CI 2.26-7.68, respectively) and each 10% change in lesion dimension on US from baseline (OR 1.15, 95%CI 1.08-1.24, and OR 1.25, 95%CI 1.16-1.35, respectively) as parameters associated with pCR.CONCLUSIONS: Our data support the use of week 3 and EOT US for prediction of pCR in response-guided NAT and in planning of breast-conserving surgery. Change in tumor diameter on US as a continuous variable could be a valuable alternative to categorical RECIST 1.1 criteria.

AB - OBJECTIVE: We assessed the value of breast ultrasound (US) performed at week 3 and 6 and at the end (EOT) of neoadjuvant therapy (NAT) for prediction of pathologic complete response (pCR, ypT0/is ypN0) in patients with HR+/HER2+, HR-/HER2-or HR-/HER2+ early breast cancer enrolled in the WSG-ADAPT subtrials.METHODS: US was performed at week 3 and 6 of NAT and at EOT in 401, 517, and 553 patients, respectively. Tumors with complete or partial response by US (RECIST 1.1) were classified as responders and those with stable or progressive disease as non-responders.RESULTS: pCR rate was higher in US responders than in non-responders. US tended to yield the highest positive predictive value in HR-/HER2+ (69%) and HR-/HER2-tumors (65%) at week 3, and the highest negative predictive value in HR+/HER2+ tumors at week 6 and at EOT (88.9% and 86.9%, respectively) and in HR-/HER2-tumors at EOT (87.9%). Multivariable analysis of patients with US at week 3 and 6 identified tumor subtype (HR-/HER2+ vs HR+/HER2+; odds ratio (OR) 2.77, 95%CI 1.45-5.29, and OR 4.17, 95%CI 2.26-7.68, respectively) and each 10% change in lesion dimension on US from baseline (OR 1.15, 95%CI 1.08-1.24, and OR 1.25, 95%CI 1.16-1.35, respectively) as parameters associated with pCR.CONCLUSIONS: Our data support the use of week 3 and EOT US for prediction of pCR in response-guided NAT and in planning of breast-conserving surgery. Change in tumor diameter on US as a continuous variable could be a valuable alternative to categorical RECIST 1.1 criteria.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms/drug therapy

KW - Female

KW - Humans

KW - Neoadjuvant Therapy

KW - Receptor, ErbB-2

KW - Ultrasonography, Mammary

U2 - 10.1016/j.breast.2021.06.001

DO - 10.1016/j.breast.2021.06.001

M3 - SCORING: Journal article

C2 - 34166854

VL - 59

SP - 58

EP - 66

JO - BREAST

JF - BREAST

SN - 0960-9776

ER -